Hans-Peter Gerber is an independent Board member and Chairman of T-CURX Board of Directors. Hans-Peter is a seasoned executive with over 25 years of experience in oncology drug development, including antibody-drug conjugates (ADCs), redirected T-cell targeting compounds (bispecifics), and adoptive T-cell therapies (TCR-T and CAR-T cells). He has built and led highly successful drug development teams in pharma, biotech, and startup companies and oversaw the preclinical development of therapeutic programs in oncology.

Hans-Peter is the co-founder of Codeable Therapeutics, an ADC startup company focusing on the development of next-generation ADCs that induce immunogenic cell death. He also serves as independent board member at Athebio, a startup company located in Basel, Switzerland, developing the next generation of DARPin biotherapeutics.

From 2018 to 2022, Hans-Peter served as CSO and SVP of 3T Biosciences, where he built up the research organization to over 30 FTEs. He oversaw target identification, platform- and preclinical program development of TCR-T cell and CD3-bispecific programs targeting pHLA complexes. He completed an oversubscribed series A round as interim CEO, where he presented to over 80 VC firms and raised a total of over $50M by June 2021.

Between 2017 and 2021, he also served as an independent director on the board of NBE Therapeutics, a clinical-stage ADC company located in Basel, Switzerland, which was acquired by Boehringer Ingelheim in Q1/21 for $1.4B.

From 2016 to 2018, Hanspeter built up the R&D organization at Maverick Therapeutics to 25 FTEs as President and CSO in the context of a "build to buy" collaboration with Takeda. Takeda exercised its option to acquire Maverick for $525M, after the Maverick team successfully filed two INDs for conditional CD3-bispecifics.

Prior to his recent roles, Hans-Peter held leadership positions at several top biopharmaceutical companies, including Genentech, Seattle Genetics, and Pfizer, where he oversaw the R&D group of over 100 FTEs in Pearl River, NY, as CSO. During this time, he oversaw the development of multiple oncology biotherapeutic programs and modalities, from discovery through IND filings. His teams contributed to three BLAs, including Avastin and two ADCs (Mylotarg, Besponsa), and he led the filing of over ten INDs for ADCs and bispecifics, of which five advanced to phase 1/2.

Hans-Peter is an author on over 100 peer-reviewed papers and reviews in high-impact journals and a co-inventor on over 100 issued patents. He received an MS in Biochemistry and a PhD in Molecular Biology from the University of Zurich, Switzerland.